Management of Thalassemia

GENERAL PRINCIPLES OF MANAGEMENT

• Goal: Maximize oxygen delivery, suppress extramedullary hematopoiesis, minimize iron overload.
• Management categories divided into conservative (blood transfusion, iron chelation), curative (hematopoietic stem cell transplant, gene therapy), and investigational (hemoglobin-inducing agents).
• Multidisciplinary approach essential for managing systemic complications.

TRANSFUSION THERAPY

• Cornerstone of Transfusion-Dependent Thalassemia (TDT) treatment.
• Aim: Suppress ineffective erythropoiesis, promote normal growth, prevent bone deformities.

Indications

• Hemoglobin (Hb) < 7 g/dL on 2 occasions > 2 weeks apart.
• Hb > 7 g/dL accompanied by specific complications:
  • Disturbance of growth and development.
  • Facial bone changes.
  • Pathologic fractures.
  • Severe extramedullary hematopoiesis.
  • Clinically significant pulmonary hypertension.

Regimens and Targets

• Moderate transfusion regimen preferred to reduce iron loading without expanding erythropoiesis.
• Pre-transfusion Hb target: 9.0-10.5 g/dL.
• Post-transfusion Hb target: 14.0-15.0 g/dL.
• Higher trough Hb (11-12 g/dL) indicated for severe heart disease or significant extramedullary hematopoiesis.
• Frequency: Transfuse every 2-5 weeks.
• Volume: 10-15 mL/kg packed red blood cells (PRBC) per session.

Blood Component Specifications

• Age of PRBCs: < 2 weeks old.
• Processing: Leukocyte-depleted to minimize non-hemolytic febrile reactions, cytomegalovirus (CMV) transmission, and HLA alloimmunization.
• Washed RBCs recommended.
• Compatibility: Match ABO, Rh (C, c, E, e), and Kell antigens to prevent alloimmunization.
• Mandatory alloantibody screening prior to every transfusion.

Complications of Transfusion

• Acute: Non-hemolytic febrile reaction, allergic/anaphylactic reaction, acute hemolytic reaction, transfusion-associated circulatory overload (TACO).
• Delayed/Long-Term: Iron overload, alloimmunization, blood-borne infections (HIV, Hepatitis B/C).

SPLENECTOMY

Indications

• Annual PRBC transfusion requirement exceeding 200-250 mL/kg/year.
• Symptomatic massive splenomegaly (pain, risk of rupture).
• Severe hypersplenism leading to cytopenias (leukopenia, thrombocytopenia).

Preoperative and Postoperative Care

• Timing: Delay until patient age >5 or >6 years to minimize sepsis risk.
• Immunization: Polyvalent pneumococcal, meningococcal, and Haemophilus influenzae type b vaccines required 2 weeks prior to surgery.
• Surgical Approach: Laparoscopic total splenectomy preferred. Partial splenectomy considered to preserve immune competence.
• Prophylaxis: Lifelong oral penicillin (e.g., 250 mg bid) post-splenectomy. Cholecystectomy performed concurrently if symptomatic gallstones present.

Complications

• Overwhelming postsplenectomy infection (OPSI) / sepsis.
• Increased risk of venous thrombosis, pulmonary hypertension, leg ulcers, and silent cerebral infarction.

PHARMACOLOGIC THERAPIES

Hemoglobin F (HbF) Inducers

• Hydroxyurea: DNA antimetabolite upregulating HbF synthesis.
  • Efficacy: Highly utilized in Non-Transfusion-Dependent Thalassemia (NTDT). Lowers risk of leg ulcers, pulmonary hypertension, and extramedullary hematopoiesis. Efficacy in TDT limited.
  • Dosage: Initial dose 10 mg/kg/day; escalate slowly to maximum 20 mg/kg/day.
  • Monitoring: Risk of significant cytopenias. Frequent CBC with differential mandated.

Erythroid Maturation Agents

• Luspatercept: Recombinant fusion protein binding TGF-beta family ligands.
  • Mechanism: Blocks signaling pathways mediating ineffective erythropoiesis. Enhances terminal erythroid maturation.
  • Dosage: 1-1.25 mg/kg administered via subcutaneous injection every 3 weeks.
  • Efficacy: Yields >33% reduction in RBC transfusion requirements in TDT. Increases Hb by 1-1.5 g/dL in NTDT.
  • Adverse Effects: Bone pain, arthralgia, dizziness, hypertension, hyperuricemia.

CURATIVE THERAPIES

Hematopoietic Stem Cell Transplantation (HSCT)

• Sole established curative modality.
• Indications: Offer early in childhood (<14 years) prior to organ damage onset (hepatomegaly, liver fibrosis, iron overload).
• Donor Selection: HLA-identical sibling donor yields >90% overall survival and 80% event-free survival. Matched Unrelated Donor (MUD) using high-resolution HLA typing shows comparable success but elevated Graft-Versus-Host Disease (GVHD) risk.
• Conditioning: Myeloablative regimens standard. Reduced intensity conditioning under clinical investigation.

Gene Therapy

• Approved for TDT patients >12 years of age (gene editing) or >4 years (gene addition).
• Gene Addition:
  • Agent: Betibeglogene autotemcel (beti-cel).
  • Mechanism: Harvest autologous CD34+ cells. Transduce ex vivo utilizing replicant-incompetent lentiviral vector carrying modified beta-globin gene (T87Q).
  • Efficacy: ~90% achieve transfusion independence.
• Gene Editing:
  • Mechanism: CRISPR-Cas9 genome editing targeting erythrocyte-specific enhancer BCL11A to increase HbF.
  • Exagamglogene autotemcel inactivates BCL11A repressor; successfully halts transfusion requirement while maintaining normal Hb levels.
• Conditioning: Requires myeloablative conditioning prior to stem cell reinfusion.

MULTIDISCIPLINARY SUPPORTIVE CARE

Endocrine and Bone Health

• Growth: Assess height/weight quarterly. Treat growth hormone deficiency.
• Hypogonadism: Administer estrogen, progesterone, or testosterone hormone replacement therapy for delayed puberty or gonadal failure.
• Bone Density: Annual DEXA scan starting age 10. Prescribe Calcium, Vitamin D, and Zinc (25 mg daily) supplementation. Administer bisphosphonates for osteoporosis.
• Glucose homeostasis: Annual Oral Glucose Tolerance Test (GTT).

Dietary and Supplement Interventions

• Folic Acid: 1 mg/day for all patients not receiving regular transfusions.
• Iron restriction: Avoid iron-fortified foods. Consumption of tea with meals decreases intestinal iron absorption.

Routine Monitoring Schedule

MANAGEMENT OF SPECIFIC SYNDROMES

Non-Transfusion-Dependent Thalassemia (NTDT) / Thalassemia Intermedia

• Phenotype: Homozygous or compound heterozygous maintaining Hb 7-10 g/dL without chronic transfusions.
• Complications: Marked medullary expansion, extramedullary hematopoiesis, leg ulcers, pulmonary hypertension, thrombosis. Extramedullary hematopoiesis compressing spinal cord requires emergent radiation.
• Transfusion therapy: Indicated for acute erythroblastopenia (Parvovirus B19), infection, pregnancy, poor growth, or severe facial bone deformities.
• Chelation therapy: Treat dietary iron overload. Indicated if transferrin saturation >70%, serum ferritin >800 ng/mL, or LIC >5 mg/g dw.
• Splenectomy: Strictly avoid if possible due to high risk of pulmonary hypertension and thromboembolism.

Alpha-Thalassemia

• Hemoglobin H (HbH) Disease (3 alpha-gene deletion):
  • Phenotype: Microcytic anemia, mild splenomegaly. Hb ranges 7-11 g/dL.
  • Management: Supportive. Avoid oxidative drugs due to HbH instability. Administer folate and multivitamins (exclude iron). Ensure Calcium/Vitamin D for bone health. Intermittent transfusions required during febrile illnesses or stressors.
• Hydrops Fetalis (4 alpha-gene deletion):
  • Phenotype: Intrauterine or early neonatal death secondary to severe anemia/hypoxia.
  • Management: Intrauterine red cell transfusions essential for fetal survival. Surviving neonates require lifelong hypertransfusion regimens or allogeneic HSCT.

ACUTE EMERGENCIES

• Sepsis: Iron overload and deferoxamine chelation highly elevate risk for Yersinia enterocolitica and encapsulated organisms. Initiate immediate broad-spectrum antibiotics upon presentation of fever.
• Cardiogenic Shock: Obtain immediate ECG, Echocardiogram (assess left ventricular contractility), and Central Venous Pressure (CVP). Institute intensive continuous IV deferoxamine (50-60 mg/kg/day over 24h) combined with deferiprone (75-99 mg/kg/day divided tid). Cautious diuresis required due to high baseline preload.
• Endocrine Crisis: Standard protocols for diabetic ketoacidosis. Administer presumptive hydrocortisone for suspected adrenal insufficiency in shock states.